首页 > 市场调查报告书 > 製药

非专利药

市场调查报告书

商品编码

1461321

非专利无菌注射剂市场：依药物类型、治疗应用、通路、地区

Generic Sterile Injectables Market, by Drug Type, by Therapeutic Application, by Distribution Channel and by Region

出版日期: 2024年03月11日 | 出版商:

Coherent Market Insights | 英文 387 Pages | 商品交期: 2-3个工作天内

价格

简介目录

至2024年，全球非专利药无菌注射剂市场估计为463.3亿美元，预计在预测期内（2024-2031年）复合年增长率为10.3%。

报告范围		报告详情
基准年	2023年	2023/2024年市场规模	463.3亿美元
实际资料	2019-2023	预测期	2024-2031
预测期2023/2024-2030/2031复合年增长率	10.30%	2030/2031 年预测值	919.1亿美元

2024 年全球非专利药无菌注射剂市场规模（十亿美元）（按地区）

非专利无菌注射是美国FDA核准的生技药品，在医疗产业的大部分领域用于治疗许多疾病和病症。非专利无菌注射剂比这些药物的品牌版本便宜得多，而且效果也一样。因此，这些注射剂的需求量始终很高，并被世界各地的大多数医院和诊所使用。然而，由于FDA对这些注射剂的生产有严格的规定，这些注射剂的严格需求满足一直是全球非专利药无菌注射剂市场主要参与企业面临的一个挑战。

随着无菌注射剂适用于各种疾病和医疗状况，非专利无菌注射市场预计在可预见的未来将获得稳定的发展。製造商正致力于增加非专利无菌注射剂的产量，以满足不断增长的需求，同时又不影响注射剂的品质。

市场动态

市场参与企业正在致力于推出非专利无菌注射剂的新产品，预计这将在预测期内促进全球非专利无菌注射剂的成长。例如，2017年6月，百特国际公司推出了可立即使用的克林霉素盐水注射液，其三种常用处方配方为：300 mg/50 mL、600 mg/50 mL和900 mg/50 mL ，美国FDA商业性核准该产品。克林霉素是一种抗生素，通常用于治疗由敏感厌氧和链球菌、肺炎球菌和葡萄球菌菌株引起的严重感染疾病，而青霉素不适合患者。

主要企业正专注于合作伙伴关係等无机活动，预计这将在预测期内促进全球非专利药无菌注射剂市场的成长。例如，2017年，诺华公司的非专利部门山德士扩大了在斯洛维尼亚的抗生素工厂，投资超过3,354万美元来开发和现代化该工厂。第一条生产线将于 2019 年启动，新生产线将于 2023 年分阶段投入使用。

该公司专注于采用收购等无机成长策略，以扩大其全球影响力并改善其国际商机。例如，2016年8月，梯瓦製药工业有限公司完成了对艾尔建学名药业务的收购。艾尔建公司是一家总部位于爱尔兰的美国製药公司。

本研究的主要特点

该报告对全球非专利药无菌注射剂市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模。
它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、区域前景、主要企业采取的竞争策略等的重要见解。
它根据公司简介、财务绩效、产品系列、地理分布、分销策略、关键发展和策略以及未来计划等参数，介绍了全球非专利无菌注射剂市场的主要企业。
该报告的见解使负责人和公司经营团队能够就未来的产品发布、技术改进、市场扩张和行销策略做出明智的决策。
全球非专利无菌注射剂市场报告针对该行业的各个相关人员，如投资者、供应商、製造商、经销商、新进业者和财务分析师。
相关人员可以透过用于分析全球非专利无菌注射剂市场的各种策略矩阵来促进他们的决策。

介绍
北美洲
美国
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲
欧洲
德国
英国
法国
义大利
西班牙
俄罗斯
欧洲其他地区
亚太地区
中国
印度
日本
澳洲
韩国
东南亚国协
其他亚太地区
中东
波湾合作理事会
以色列
其他中东地区
非洲
南非
中部非洲
北非

第9章竞争格局

公司简介
- Baxter International Inc.
- AstraZeneca plc
- Merck &Co., Inc.
- Pfizer Inc.
- Fresenius Kabi
- Novartis International AG
- Teva Pharmaceuticals
- Hikma Pharmaceuticals
- Reddy's Laboratory
- Mylan NV
- Sun Pharmaceutical Industries Ltd.

第10章分析师建议

繁荣与衰落
综合机会图

第11章章节

参考
调查方法

简介目录

Product Code: CMI519

Global generic sterile injectables market is estimated to be valued at USD 46.33 Bn in 2024 and is expected to exhibit a CAGR of 10.3% during the forecast period (2024-2031).

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 46.33 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	10.30%	2030/2031 Value Projection:	US$ 91.91 Bn

Global Generic Sterile Injectables Market Value (US$ Bn), by Region, 2024

Generic Sterile Injectables Market - IMG1

The generic sterile injectable are U.S. FDA approved biologics that are used for the treatment of many diseases and disorders in the vast arena of the healthcare industry. The generic sterile injectable are very inexpensive as compared to that of their branded counterparts of these drugs and performs equally well. Thus, these Injectables are heavily in demand all the time and are used in majority of hospitals and clinics across the globe. However, due to the stringent FDA regulations for the production of these injectable, the rigorous demand satisfaction of these injectable has always been a constant challenge for the key players in the global generic sterile injectable market.

The generic sterile injectable market is expected to gain steady traction in the foreseeable future as the sterile injectable products find its application across a wide number of diseases and medical condition. Manufacturers are focused on increasing the production of generic sterile injectable to meet the rising demands without compromising on the quality of the injectable.

Market Dynamics

Market players are engaged in launching new products for generic sterile injectables, this is expected to increase the growth of the global generic sterile injectables, over the forecast period. For instance, in June 2017, Baxter International Inc. announced the U.S. FDA approval and commercial launch of ready-to-use clindamycin injection in saline in three commonly prescribed formulations (300mg/50mL, 600mg/50mL, and 900mg/50mL). Clindamycin is a widely prescribed antibiotic for serious infections which is caused by susceptible anaerobic bacteria and strains of streptococci, pneumococci and staphylococci, when penicillin is inappropriate for a patient.

Key players are focusing on inorganic activities such as partnerships, this is expected to increase the growth of the global generic sterile injectables market, over the forecast period. For instance, in 2017, Novartis' generic arm Sandoz expanded its antibiotic facility in Slovenia, with an investment of over US$ 33.54 million aimed at the development and modernization of facilities. The first production lines started in 2019, after which new lines will be gradually phased in by 2023.

The company is focused on adopting inorganic growth strategies such as acquisitions to expand its global presence and improve international commercial opportunities. For instance, in August 2016, Teva Pharmaceutical Industries Ltd. completed the acquisition of Allergan's generics business. Allergan plc.is an American, Irish-domiciled pharmaceutical company.

Key features of the study:

This report provides an in-depth analysis of the global generic sterile injectables market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global generic sterile injectables market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Baxter International Inc., AstraZeneca plc, Merck & Co., Inc., Pfizer Inc., Fresenius Kabi, Novartis International AG, Teva Pharmaceuticals, Hikma Pharmaceuticals, Dr. Reddy's Laboratory, Mylan N.V., and Sun Pharmaceutical Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global generic sterile injectables market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global generic sterile injectables market

Detailed Segmentation:

Global Generic Sterile Injectables Market, By Drug Type:
- Monoclonal Antibodies
- Cytokines
- Insulin
- Peptide Hormones
- Vaccines
- Immunoglobulins
- Blood Factors
- Antibiotics
- Others
Global Generic Sterile Injectables Market, By Therapeutic Application:
- Cancer
- Metabolic Diseases
- Cardiovascular Diseases
- Central Nervous System Disease
- Infectious Disorders
- Musculoskeletal Disorders
- Others
Global Generic Sterile Injectables Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Generic Sterile Injectables Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Baxter International Inc.
- AstraZeneca plc
- Merck & Co., Inc.
- Pfizer Inc.
- Fresenius Kabi
- Novartis International AG
- Teva Pharmaceuticals
- Hikma Pharmaceuticals
- Reddy's Laboratory
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Therapeutic Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Regulatory Scenario
PEST Analysis
Recent Product Launch/Approval
Epidemiology
Mergers and Acquisitions

4. Global Generic Sterile Injectables Market - Impact of Coronavirus (Covid-19) Pandemic

Impact on Supply Chain
Impact on Research and Development
Government Initiatives

5. Global Generic Sterile Injectables Market, By Drug Type, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Cytokines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Peptide Hormones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Immunoglobulins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Blood Factors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)

6. Global Generic Sterile Injectables Market, By Therapeutic Application, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Metabolic Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Central Nervous System Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Infectious Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Musculoskeletal Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)

7. Global Generic Sterile Injectables Market, By Distribution Channel, 2019 - 2031 (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD Bn)

8. Global Generic Sterile Injectables Market, By Region, 2019 - 2031 (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Regions, 2019 - 2031
- Regional Trends
North America
- Market Size and Forecast, By Drug Type, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Country, 2019 - 2031 (US$ Bn)
U.S.
Canada
Latin America
- Market Size and Forecast, By Drug Type, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Country, 2019 - 2031 (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Drug Type, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Country, 2019 - 2031 (US$ Bn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Type, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Country, 2019 - 2031 (US$ Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Type, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Country, 2019 - 2031 (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Drug Type, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (US$ Bn)
- Market Size and Forecast, By Country, 2019 - 2031 (US$ Bn)
South Africa
Central Africa
North Africa

9. Competitive Landscape

Company Profiles
- Baxter International Inc.
Company Overview
Drug Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- AstraZeneca plc
Company Overview
Drug Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Merck & Co., Inc.
Company Overview
Drug Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Pfizer Inc.
Company Overview
Drug Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Fresenius Kabi
- Novartis International AG
- Teva Pharmaceuticals
- Hikma Pharmaceuticals
- Reddy's Laboratory
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.

10. Analyst Recommendation

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. Section

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

非专利无菌注射剂市场：依药物类型、治疗应用、通路、地区